fluoxetine has been researched along with Birth Weight in 8 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Birth Weight: The mass or quantity of heaviness of an individual at BIRTH. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the present study was to compare the toxic effects of fluoxetine (F) (8 and 16 mg/kg) and venlafaxine (V) (40 and 80 mg/kg) administered during the third week of pregnancy on early development of rats." | 7.70 | Postnatal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy. ( Altenburg, SP; da-Silva, VA; Lindsey, CJ; Malheiros, LR; Thomaz, TG, 1999) |
| "No differences in birth weight and acute neonatal outcome were evident across the two groups, though there was a higher frequency of special care nursery admissions for infants with exposure to fluoxetine late in pregnancy." | 5.09 | Birth outcomes following prenatal exposure to fluoxetine. ( Ablon, JS; Bailey, JW; Bouffard, SM; Cohen, LS; Grush, L; Heller, VL, 2000) |
| " A high dose of in utero fluoxetine resulted in a decrease in birth weight of the offspring and also reduced weight gain during the preweaning period." | 3.74 | Developmental and behavioral consequences of prenatal fluoxetine. ( Ashok, KP; Bairy, I; Bairy, KL; Madhyastha, S; Malini, S, 2007) |
| "The aim of the present study was to compare the toxic effects of fluoxetine (F) (8 and 16 mg/kg) and venlafaxine (V) (40 and 80 mg/kg) administered during the third week of pregnancy on early development of rats." | 3.70 | Postnatal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy. ( Altenburg, SP; da-Silva, VA; Lindsey, CJ; Malheiros, LR; Thomaz, TG, 1999) |
| "The rate of spontaneous pregnancy loss did not differ significantly between the women treated with fluoxetine and the control women (10." | 3.69 | Birth outcomes in pregnant women taking fluoxetine. ( Chambers, CD; Dick, LM; Felix, RJ; Johnson, KA; Jones, KL, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Diav-Citrin, O | 1 |
| Shechtman, S | 1 |
| Weinbaum, D | 1 |
| Wajnberg, R | 1 |
| Avgil, M | 1 |
| Di Gianantonio, E | 1 |
| Clementi, M | 1 |
| Weber-Schoendorfer, C | 1 |
| Schaefer, C | 1 |
| Ornoy, A | 1 |
| Davidson, S | 1 |
| Prokonov, D | 1 |
| Taler, M | 1 |
| Maayan, R | 1 |
| Harell, D | 1 |
| Gil-Ad, I | 1 |
| Weizman, A | 1 |
| Bairy, KL | 1 |
| Madhyastha, S | 1 |
| Ashok, KP | 1 |
| Bairy, I | 1 |
| Malini, S | 1 |
| Pereira, JD | 1 |
| Caricati-Neto, A | 1 |
| Jurkiewicz, A | 1 |
| Jurkiewicz, NH | 1 |
| Stanford, MS | 1 |
| Patton, JH | 1 |
| Chambers, CD | 1 |
| Johnson, KA | 1 |
| Dick, LM | 1 |
| Felix, RJ | 1 |
| Jones, KL | 1 |
| da-Silva, VA | 1 |
| Altenburg, SP | 1 |
| Malheiros, LR | 1 |
| Thomaz, TG | 1 |
| Lindsey, CJ | 1 |
| Cohen, LS | 1 |
| Heller, VL | 1 |
| Bailey, JW | 1 |
| Grush, L | 1 |
| Ablon, JS | 1 |
| Bouffard, SM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Transcranial Direct Current Stimulation (tDCS) for Depression in Pregnancy: A Pilot Study[NCT02116127] | 20 participants (Actual) | Interventional | 2014-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for fluoxetine and Birth Weight
| Article | Year |
|---|---|
Birth outcomes following prenatal exposure to fluoxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Apgar Score; Birth Weight; Female; Fluoxetine; Gest | 2000 |
7 other studies available for fluoxetine and Birth Weight
| Article | Year |
|---|---|
Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study.
Topics: Abnormalities, Drug-Induced; Abortion, Induced; Adult; Antidepressive Agents, Second-Generation; Bir | 2008 |
Effect of exposure to selective serotonin reuptake inhibitors in utero on fetal growth: potential role for the IGF-I and HPA axes.
Topics: Adult; Birth Weight; Case-Control Studies; Citalopram; Female; Fetal Blood; Fetal Development; Fetal | 2009 |
Developmental and behavioral consequences of prenatal fluoxetine.
Topics: Administration, Oral; Animals; Animals, Newborn; Behavior, Animal; Birth Weight; Dose-Response Relat | 2007 |
Decreased noradrenergic and serotonergic reactivity of vas deferens of newborn rats from mothers treated with the serotonin reuptake inhibitor fluoxetine during pregnancy and breast-feeding.
Topics: Animals; Animals, Newborn; Barium; Birth Weight; Calcium; Dose-Response Relationship, Drug; Electric | 2007 |
In utero exposure to fluoxetine HCl increases hematoma frequency at birth.
Topics: Animals; Animals, Newborn; Birth Weight; Female; Fetal Viability; Fluoxetine; Hematoma; Male; Pregna | 1993 |
Birth outcomes in pregnant women taking fluoxetine.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Affective Symptoms; Birth Weight; Case-Co | 1996 |
Postnatal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy.
Topics: Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Birth Weight; Body Weight; Cycl | 1999 |